FDA approves first drug for common form of liver inflammation
The US Food and Drug Administration has approved the first medication for a common form of liver inflammation called nonalcoholic steatohepatitis, or NASH, the agency said Thursday. NASH — also known as metabolic dysfunction-associated steatohepatitis, or MASH — happens when the liver becomes…#nash #fda #rezdiffra #breakthroughtherapy #wayneeskridge #fattyliverfoundation #madrigal #pierregholam #universityhospitals #cleveland (Source: Reuters: Health)
Source: Reuters: Health - March 15, 2024 Category: Consumer Health News Source Type: news
EHR Alerts Trigger Primary Care Clinics to Improve Hypertension Care in CKD
(MedPage Today) -- A computerized clinical decision support (CDS) tool for primary care helped lower blood pressure (BP) in patients with chronic kidney disease (CKD) and uncontrolled hypertension, a cluster-randomized trial found.
When primary... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 15, 2024 Category: Cardiology Source Type: news
Kidney patients offered ‘risky’ technique
Jasna Macanovic was sacked after questioning a "risky" dialysis practice championed by ex-colleagues. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - March 15, 2024 Category: Consumer Health News Source Type: news
FDA Approves First Drug for Common, Serious Liver Disease, Rezdiffra
FRIDAY, March 15, 2024 -- Millions of Americans whose livers develop scar tissue due to a common disease now have the first approved drug, Rezdiffra, to treat the condition, the U.S. Food and Drug Administration announced Thursday.
The condition is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 15, 2024 Category: General Medicine Source Type: news
Waterborne Parasite That Can Kill Dogs Is Spreading to U.S. West
FRIDAY, March 15, 2024 -- A parasite that can kill dogs has been found in a portion of the Colorado River that runs through Southern California.
Heterobilharzia americana is a flatworm usually referred as liver fluke. It has never been reported... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 15, 2024 Category: General Medicine Source Type: news
FAPI-PET/CT outperforms FDG-PET/CT in women with invasive breast cancer
This study underscores Ga-68 FAPI-PET/CT’s superiority over F-18 FDG-PET/CT for ILC,” the group concluded. A link to the full study can be found here. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 15, 2024 Category: Radiology Authors: Will Morton Tags: Breast Source Type: news
US FDA approves first drug for fatty liver disease NASH
(Source: Reuters: Health)
Source: Reuters: Health - March 15, 2024 Category: Consumer Health News Source Type: news
FDA Approves First Drug for MASH FDA Approves First Drug for MASH
Resmetirom, a thyroid hormone receptor beta-selective agonist, is the first FDA-approved medication for MASH with moderate to advanced liver fibrosis.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - March 14, 2024 Category: Internal Medicine Tags: Gastroenterology Source Type: news
Shares of Madrigal Pharmaceuticals soar on FDA approval for NASH treatment
Conshohocken-based Madrigal Pharmaceutical has emerged as the winner in the race to be the first drug company to secure approval for a treatment targeting a liver disease known as NASH. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 14, 2024 Category: Biotechnology Authors: John George Source Type: news
FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease
The FDA approved the first medication for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring, to be used along with diet and exercise. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 14, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves First-Ever Drug for Serious Liver Condition
(MedPage Today) -- The FDA granted accelerated approval to resmetirom (Rezdiffra) as the first treatment for adults with noncirrhotic non-alcoholic steatohepatitis (NASH), also now referred to as metabolic dysfunction-associated steatohepatitis... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 14, 2024 Category: American Health Source Type: news
How to drink apple cider vinegar safely: As study suggests downing the liquid is a 'weight loss hack' we reveal the potential dangers
Apple cider vinegar is said to help weight loss and even control blood sugar. But glugging too much of the sour liquid can cause your teeth to rot, make you feel nauseous and even effect kidney function. (Source: the Mail online | Health)
Source: the Mail online | Health - March 14, 2024 Category: Consumer Health News Source Type: news
Konica Minolta applauds winner, runners up of SPIE research award
Konica Minolta Healthcare Americas congratulates the winner and runners-up of the Best Student Paper Award given by the International Society for Optics and Photonics (SPIE) at its 2024 Medical Imaging Symposium in San Diego, CA.
Konica Minolta sponsored the award as part of its continued commitment to the education and support of young scientists in medical imaging.
The winner was Olivia F. Sandvold, a doctoral student in the Department of Bioengineering at the University of Pennsylvania for her paper, “Hybrid spectral CT system with clinical rapid kVp-switching x-ray tube and dual-layer detector for improved iodin...
Source: AuntMinnie.com Headlines - March 14, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
A Blood Test for Colon Cancer Shows Promise
A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.
The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
[time-brightcove not-tgx=”true”]
In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold stan...
Source: TIME: Health - March 14, 2024 Category: Consumer Health News Authors: Carla K. Johnson/AP Tags: Uncategorized healthscienceclimate wire Source Type: news
Race, Ethnicity Plays Role in Liver Transplant Survival
THURSDAY, March 14, 2024 -- Researchers hope findings from a new study of liver transplant patients will lead to improved interventions for those from racial and ethnic minority groups.
The study— led by researchers at UT Southwestern... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 14, 2024 Category: General Medicine Source Type: news
